Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
about
Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration.Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancerEGFR expression in gallbladder carcinoma in North America.Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinomaGemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trialGemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experienceMultimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma.Systemic Therapy of Cholangiocarcinoma.Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liverCurrent management of gallbladder carcinoma.Hepatocellular carcinoma: therapy and prevention.Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.Phase II study of S-1 in patients with advanced biliary tract cancer.A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1.Therapeutical concepts and results for Klatskin tumorsThe role of chemotherapy in biliary tract carcinoma.Cholangiocarcinoma: a compact review of the literature.Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines.Advances in the management of biliary tract cancersHilar cholangiocarcinoma: expert consensus statement.Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase.Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
P2860
Q30359582-3843FED1-9919-48F2-B3BF-57B02490CE18Q33214444-E1A7EE58-A522-4E6D-A6A2-C38217F2BA6AQ33372640-7A996D5C-8C73-4089-B8EF-4078515DC9E6Q33372792-AA6046F6-BBC4-411F-9094-049965E50BF2Q33375557-9F3B670C-C128-4522-90C8-2286231FBE1DQ33391003-41239465-44EE-4941-AEA5-78D337850DD9Q33395245-89547920-1DD7-4A42-A260-E0C05D8D7918Q33402113-F1821E70-C259-48AA-98E1-ECCE29A9893EQ34339629-6A0E6608-9139-4099-B7BD-50F21CD16488Q34551877-0F0C4CF0-33F5-4AEF-BCBB-1FECC8B87B07Q34605189-2D0DDE97-9AFA-4314-85C8-97379772E89CQ35583920-D953E022-74ED-4BF2-92E4-84FB2A0CF720Q36377949-42586866-8A08-4041-8A26-41554B425107Q36671639-DE754B70-D49E-49EB-9E39-3CDC72148AE6Q36696249-066666D0-5AF7-4029-AC6C-C4ADD44FAD1BQ36868758-A71798C4-7517-4CC9-8484-DF1C06542898Q37228433-3D5E15BD-2334-41AD-B508-21B7297E9AB7Q37261360-9A8C180B-D5B6-4556-874B-06DB357516B9Q37333717-967182A2-EBAA-4B80-89FC-54877B9EEE38Q37347327-68CBB7EC-9A2B-4355-8B2B-7459DA3B6CEFQ37362900-720B157F-86F8-4B40-894D-7B41D6504EA8Q37694481-AAF7EBC7-C022-4175-8504-144B7BF3E0B4Q38082318-95E066E4-0515-43D9-B7C5-8BD893518655Q38546730-D6D2AADB-5BA0-4D99-84F9-783C6194779DQ38631350-83ABFF6B-564F-4DF1-874B-4E848198514FQ39289689-843048C2-13A6-475A-8207-147AB8F320BDQ42053469-7B6DAA0F-E33C-484D-A712-B9C708917B96Q49178298-50A47BD3-DC3B-46F5-B7F6-A80A8D31CD65
P2860
Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@ast
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@en
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@nl
type
label
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@ast
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@en
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@nl
prefLabel
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@ast
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@en
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@nl
P2093
P1476
Phase II study of systemic gem ...... able hepatobiliary carcinomas.
@en
P2093
P304
P577
2001-05-01T00:00:00Z